Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

5.130 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 28, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Tuesday ↗

February 28, 2023

During Tuesday, 79 stocks hit new 52-week lows.

Via Benzinga

Preview: Atea Pharmaceuticals's Earnings ↗

February 27, 2023

Via Benzinga

Atea Pharma's Investigational Dengue Treatment Fast Tracked In US ↗

September 26, 2022

Via Benzinga

Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023

February 23, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023

February 21, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections

February 15, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Wednesday ↗

February 15, 2023

On Wednesday, 35 stocks hit new 52-week lows.

Via Benzinga

Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir ↗

September 13, 2022

Via Benzinga

Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

February 07, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Highlights Strategic Priorities for 2023

January 09, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

November 29, 2022

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Recap: Atea Pharmaceuticals Q2 Earnings ↗

August 08, 2022

Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Short Volatility Alert: Atea Pharmaceuticals ↗

May 18, 2022

On Tuesday, shares of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) experienced volatile short activity. After the activity, the stock price went down -1.73% to $7.38. The...

Via Benzinga

Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

November 22, 2022

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference

November 08, 2022

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

November 07, 2022

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals: Q1 Earnings Insights ↗

May 10, 2022

Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Atea Pharmaceuticals Earnings Preview ↗

November 04, 2022

Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Atea...

Via Benzinga

Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting

November 03, 2022

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022

October 31, 2022

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion? ↗

July 07, 2022

Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?

Via Investor's Business Daily

Stocks Selling For Less Than Cash Per Share ↗

July 03, 2022

How do you go about choosing a stock to buy in these volatile times? One strategy is to look for stocks that are not only selling below their book value, but also below their cash per share, especially...

Via Talk Markets

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Preview For Atea Pharmaceuticals ↗

May 09, 2022

Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Atea...

Via Benzinga

How To Attend Atea Pharmaceuticals Q1 2022 Earnings Conference Call ↗

May 05, 2022

Atea Pharmaceuticals (NASDAQ:AVIR) will host a conference call at 10:00 AM ET on May 10, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

April 25, 2022

What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be...

Via Benzinga

NASDAQ:AVIR Investor Notice: Investigation over Potential Wrongdoing at Atea Pharmaceuticals, Inc. ↗

April 05, 2022

San Diego, CA -- (SBWIRE) -- 04/05/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Atea Pharmaceuticals, Inc.

Via SBWire

30 Stocks Moving in Tuesday's Pre-Market Session ↗

March 15, 2022

Gainers Incannex Healthcare Limited (NASDAQ: IXHL) rose 118.2% to $49.97 in pre-market trading after jumping 54% on Monday. Incannex Healthcare recently completed a preliminary...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.